Intelligent Bio Solutions’ Innovative Drug Screening Technology Now Offered in New Zealand
24 Ottobre 2023 - 2:30PM
Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the
“Company”), a medical technology company delivering intelligent,
rapid, non-invasive testing solutions, today announced its
expansion into the New Zealand market, representing a significant
milestone in the Company’s growth strategy for its Intelligent
Fingerprinting Drug Screening System.
Drug-related harm in New Zealand equates to a
staggering $1.9 billion each year1, with significant societal
consequences across communities, workplaces and more. New Zealand
employers have a responsibility under the Health and Safety in
Employment Act 1992 (HSE Act) to ensure the provision of a safe
workplace and take all reasonable measures to safeguard employees
while at work2. The HSE Act further requires significant hazards to
employees, such as the behaviour of an employee affected by alcohol
or drugs, to be eliminated, isolated and minimized3. The Company’s
Intelligent Fingerprinting Drug Screening System, which uses
fingertip sweat to screen for common drugs of abuse, helps
employers to fulfil these legal obligations by offering an
efficient, dignified, and non-invasive alternative to traditional
and more intrusive point-of-care drug testing methods.
Harry Simeonidis, President and CEO of
Intelligent Bio Solutions, said, “We are delighted to announce our
expansion into New Zealand and observe another key growth
milestone. Our primary focus is to meet the screening needs and
support the health and safety initiatives of businesses across New
Zealand and around the world. Drawing on our success in Australia
over the past six months, we aim to continue this progress in New
Zealand and other markets by offering an alternative and innovative
solution that places a strong emphasis on operational efficiency,
fitness for duty, and employee privacy and dignity.”
The Company’s Intelligent Fingerprinting Drug
Screening System is currently available throughout Australia, the
United Kingdom, South America, and parts of Europe and Asia,
including Spain and Nepal. In addition to these locations, the
Company’s growth plan includes further expansion throughout Asia
Pacific, the United States and Canada.
About Intelligent Bio Solutions
Inc.
Intelligent Bio Solutions Inc. (the “Company”)
(Nasdaq: INBS) is a medical technology company delivering
intelligent, rapid, non-invasive testing solutions. The Company
believes that its Intelligent Fingerprinting Drug Screening System
will revolutionize portable testing through fingerprint sweat
analysis, which has the potential for broader applications in
additional fields. This hygienic, and cost-effective system is
designed to screen for recent use of drugs commonly found in the
workplace, including opioids, cocaine, methamphetamine, and
cannabis. With sample collection in seconds and results in under
ten minutes, this technology would be a valuable tool for employers
in safety-critical industries. Additionally, the Company's
biosensor platform has the potential to test for up to 130
indications, ranging from glucose to immunological conditions and
communicable diseases. The Company’s current customer segments
include construction, manufacturing and engineering, transport and
logistics firms, drug treatment organizations, and coroners.
For more information,
visit: www.ibs.inc
Forward-Looking Statements:
Some of the statements in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.’s ability to successfully develop and commercialize
its drug and diagnostic tests, realize commercial benefit from its
partnerships and collaborations, and secure regulatory approvals,
among others. Although Intelligent Bio Solutions
Inc. believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking
statements. Intelligent Bio Solutions Inc. has attempted
to identify forward-looking statements by terminology, including
“believes,” “estimates,” “anticipates,” “expects,” “plans,”
“projects,” “intends,” “potential,” “may,” “could,” “might,”
“will,” “should,” “approximately” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, included in Intelligent Bio Solutions’ public filings
filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this release speak only as
of its date. Intelligent Bio Solutions undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company Contact:Intelligent Bio
Solutions Inc.info@ibs.inc
Investor Contact:Valter Pinto,
Managing DirectorKCSA Strategic CommunicationsPH: (212)
896-1254INBS@kcsa.com
Media Contact:Cheryl BillsonComma
Communicationscheryl.billson@commacomms.com
1
https://www.drugfoundation.org.nz/policy-and-advocacy/drugs-in-nz-an-overview/
2
https://www.supportadventure.co.nz/assets/Uploads/ACC-alcohol-and-drugs-in-the-workplace.pdf
3
https://www.legislation.govt.nz/act/public/1992/0096/latest/DLM278829.html
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Intelligent Bio Solutions (NASDAQ:INBS)
Storico
Da Giu 2023 a Giu 2024